Literature DB >> 3794095

Alterations in left ventricular diastolic function with doxorubicin therapy.

B H Lee, L S Goodenday, G J Muswick, W A Yasnoff, R F Leighton, R T Skeel.   

Abstract

To determine whether impaired diastolic function may be an early sign of doxorubicin cardiotoxicity, a retrospective study was performed in 12 patients who had undergone serial radionuclide angiography and were found to have a left ventricular ejection fraction of 55% or more before doxorubicin (Adriamycin) treatment and during follow-up. Average rapid filling velocity and slow filling velocity were both significantly reduced after doxorubicin treatment. Rapid filling velocity decreased from 5.17 +/- 1.52 to 4.18 +/- 0.96 units/s (p less than 0.01), and slow filling velocity decreased from 2.20 +/- 1.32 to 1.42 +/- 0.62 units/s (p less than 0.05). There were no significant changes in filling volume ratio, total diastolic time or diastolic time ratio. Because a change in left ventricular diastolic function can occur before ejection fraction falls to subnormal levels, diastolic function as well as systolic function should be examined for the early detection of doxorubicin cardiotoxicity. The clinical implications of our observations can only be established by a longer-term prospective analysis of left ventricular function in patients receiving doxorubicin therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3794095     DOI: 10.1016/s0735-1097(87)80099-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  20 in total

1.  Diastolic or systolic left and right ventricular impairment at moderate doses of anthracycline? A 1-year follow-up study of women.

Authors:  Y Cottin; C Touzery; B Coudert; S Richebourg; M Cohen; M Toubeau; P Louis; J E Wolf; F Brunotte
Journal:  Eur J Nucl Med       Date:  1996-05

2.  Ventricular function during the acute rejection of heterotopic transplanted heart: gated blood-pool studies.

Authors:  H Valette; M H Bourguignon; M Desruennes; P Merlet; D Le Guludec; M C Gregoire; D Agostini; M Rigaud; I Gandjbakhch; A Cabrol
Journal:  Eur J Nucl Med       Date:  1991

3.  Left Ventricular Regional Wall Motion Abnormality is a Strong Predictor of Cardiotoxicity in Breast Cancer Patients Undergoing Chemotherapy.

Authors:  Márcio Vinícius Lins de Barros; Ariane Vieira Scarlatelli Macedo; Sebastian Imre Sarvari; Monica Hermont Faleiros; Patricia Tavares Felipe; Jose Luiz Padilha Silva; Thor Edvardsen
Journal:  Arq Bras Cardiol       Date:  2018-12-13       Impact factor: 2.000

4.  Can serial changes of diastolic dysfunction signal incremental risk of chemotherapy-induced heart failure missed by the timing of declining LV ejection fraction?

Authors:  Ronald G Schwartz; Nicholas Venci
Journal:  J Nucl Cardiol       Date:  2015-07-24       Impact factor: 5.952

5.  Assessing anthracycline cardiotoxicity in the 1990s.

Authors:  I Carrió; M Estorch; A López-Pousa
Journal:  Eur J Nucl Med       Date:  1996-04

6.  Assessing the Cardiac Toxicity of Chemotherapeutic Agents: Role of Echocardiography.

Authors:  Timothy C Tan; Marielle Scherrer-Crosbie
Journal:  Curr Cardiovasc Imaging Rep       Date:  2012-12-01

7.  Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology.

Authors:  F A Bu'Lock; M G Mott; A Oakhill; R P Martin
Journal:  Br Heart J       Date:  1995-04

8.  Epirubicin cardiotoxicity: a study comparing low- with high-dose-intensity weekly schedules.

Authors:  G J Berchem; F Ries; J Hanfelt; C Duhem; M Keipes; C Delagardelle; M Dicato
Journal:  Support Care Cancer       Date:  1996-07       Impact factor: 3.603

9.  Assessment of left ventricular diastolic function in patients receiving anthracycline therapy.

Authors:  S Parmentier; J A Melin; L Piret; C Beckers
Journal:  Eur J Nucl Med       Date:  1988

10.  Cardiac complications of chemotherapy: role of imaging.

Authors:  Timothy C Tan; Marielle Scherrer-Crosbie
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.